Vesatolimod

Drug Profile

Vesatolimod

Alternative Names: GS-9620

Latest Information Update: 25 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Gilead Sciences
  • Class Antivirals; Pteridines; Pyrrolidines; Small molecules
  • Mechanism of Action Toll-like receptor 7 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis B
  • Phase I HIV-1 infections
  • Discontinued Hepatitis C

Most Recent Events

  • 17 Apr 2017 Gilead Sciences initiates enrolment in a phase Ib trial for HIV-1 infections in USA (NCT03060447)
  • 02 Mar 2017 Gilead Sciences plans a phase Ib trial for HIV-1 infection in USA (NCT03060447)
  • 13 Feb 2017 Preclinical data in HIV-1 infections presented at the 24th Conference on Retroviruses and Opportunistic Infections (CROI-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top